{
  "id": 110215,
  "name": "NOVARTIS",
  "slug": "novartis",
  "state": "DC",
  "description": "Multinational biopharmaceutical company",
  "totalSpending": 1810000,
  "filings": 30,
  "yearlySpending": [
    {
      "year": 2019,
      "income": 220000
    },
    {
      "year": 2020,
      "income": 270000
    },
    {
      "year": 2021,
      "income": 280000
    },
    {
      "year": 2022,
      "income": 200000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 300000
    },
    {
      "year": 2025,
      "income": 300000
    }
  ],
  "firms": [
    "BROWNSTEIN HYATT FARBER SCHRECK, LLP"
  ],
  "lobbyists": [
    "MARC LAMPKIN",
    "ZACHARY PFISTER",
    "BRIAN WILD",
    "BRIAN MCKEON",
    "NADEAM ELSHAMI",
    "JEROME MURRAY",
    "LAURA BOLLIER",
    "EMILY FELDER",
    "ROSEMARY BECCHI",
    "RADHA MOHAN",
    "ARACELI GUTIERREZ",
    "DOUGLAS MAGUIRE",
    "ADAM STEINMETZ",
    "R. NICHOLSON",
    "BRIAN MCGUIRE",
    "DEEMA TARAZI",
    "GREGORY SUNSTRUM",
    "ANDREW USYK",
    "DAVID REID",
    "BRANDT ANDERSON",
    "JOHN REISING",
    "MAXWELL HUNTLEY",
    "STEPHEN HOLLAND"
  ],
  "issues": [
    "HCR",
    "ENV",
    "TAX",
    "MED",
    "VET",
    "IMM",
    null
  ],
  "sampleDescriptions": [
    "Issues related to cell and gene therapy, development of therapies for rare diseases, pharmaceutical pricing; Issues related to corporate environmental sustainability",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases",
    "Issues related to corporate environmental sustainability",
    "Tax filing programs",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases\nH.R. 748 CARES Act, Issues related to COVID-19 treatment",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases\nIssues related to COVID-19",
    "Opportunities for health care collaboration",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases, Issues related to COVID-19",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases, Issues related to COVID-19 treatment\nH.R.1319 - American Rescue Plan Act of 2021",
    "Issues related to cell and gene therapy\nPharmaceutical pricing\nIssues related to the development of therapies for rare diseases, Issues related to COVID-19 treatment",
    "Issues related to visas",
    "Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases, Issues related to COVID-19 Issues related to reconciliation 340B Drug Discount Program Issues related to PDUFA and pharmaceutical IP",
    "Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases Issues related to COVID-19 H.R.5376 - Inflation Reduction Act of 2022 Issues related to Cancer Moonshot 340B Drug Discount Program Issues related to PDUFA and pharmaceutical IP",
    "Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases, Issues related to COVID-19 Issues related to reconciliation 340B Drug Discount Program Issues related to PDUFA and pharmaceutical IP H.R.5376 - Inflation Reduction Act of 2022 Issues related to pharmacy benefit managers (PBMs) H.R. 2617 Consolidated Appropriations Act, 2023 Supply chain issues affecting pharmaceutical products",
    "Opportunities for health care collaboration Issues related to Medicare and Medicaid for Veterans",
    "Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act",
    "Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues",
    "Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues",
    "Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act",
    "Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy"
  ],
  "years": [
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 36,
  "trajectory": "growing",
  "yearsActive": 7,
  "avgAnnualSpending": 258571,
  "peakYear": 2024,
  "lobbyistCount": 23,
  "firmCount": 1,
  "issueCount": 6
}